Stem Cell gets green light to continue trial

A Data Safety Monitoring Board has given Stem Cell Therapeutics the go-ahead to continue with the Phase IIb trial of Regenesis, a medication designed to improve recovery after an acute ischemic stroke. Stem Cell Therapeutics release